ReviewCureus2026
Lacosamide Use After Traumatic Brain Injury: A Scoping Review.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lacosamide (LCM) is a newer antiepileptic drug that enhances slow inactivation of voltage-gated sodium channels and modulates collapsin response mediator protein-2, suggesting potential roles in seizure control and axonal protection after traumatic brain injury (TBI). However, its role in TBI remains unclear. This scoping review aimed to characterize preclinical and clinical research on LCM use in TBI, focusing on seizure prophylaxis, seizure treatment, and potential neuroprotective effects. A comprehensive search of MEDLINE, Cochrane Central Register of Controlled Trials (CENTRAL), Cumulative Index of Nursing and Allied Health (CINAHL), Web of Science, and ClinicalTrials.gov was conducted. Studies involving human patients or animal TBI models evaluating acute LCM use were included, and data were charted descriptively. Ten studies were included, comprising five preclinical and five clinical investigations. Preclinical studies evaluated seizure-related, electrophysiological, histological, inflammatory, and behavioral outcomes in experimental TBI models. Clinical studies included two randomized trials, two observational cohorts, and one case report involving patients with moderate to severe TBI. LCM was administered for seizure prophylaxis or treatment. Seizure-related and safety outcomes were reported across clinical studies, whereas neurological and functional outcomes were less consistently assessed. Overall, evidence supporting LCM use in acute TBI remains limited, with differences between preclinical and clinical outcome domains.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.